Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a US health plan population.

被引:1
作者
Signorovitch, James
Zhou, Zhou
Ryan, Jason
Chawla, Anita
机构
[1] Anal Grp Inc, Boston, MA USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Anal Grp Inc, Menlo Pk, CA USA
关键词
D O I
10.1200/JCO.2017.35.15_suppl.6599
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
6599
引用
收藏
页数:5
相关论文
empty
未找到相关数据